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Abstract
Differences in genomic structure between individuals are ubiquitous features of human genetic variation. Specific copy
number variants (CNVs) have been associated with susceptibility to numerous complex psychiatric disorders, including
attention-deficit-hyperactivity disorder, autism-spectrum disorders and schizophrenia. These disorders often display co-
morbidity with low intelligence. Rare chromosomal deletions and duplications are associated with these disorders, so it has
been suggested that these deletions or duplications may be associated with differences in intelligence. Here we investigate
associations between large ($500kb), rare (,1% population frequency) CNVs and both fluid and crystallized intelligence in
community-dwelling older people. We observe no significant associations between intelligence and total CNV load.
Examining individual CNV regions previously implicated in neuropsychological disorders, we find suggestive evidence that
CNV regions around SHANK3 are associated with fluid intelligence as derived from a battery of cognitive tests. This is the
first study to examine the effects of rare CNVs as called by multiple algorithms on cognition in a large non-clinical sample,
and finds no effects of such variants on general cognitive ability.
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Introduction
Among humans, individual differences in measured intelligence
are associated with important life outcomes, including long-term
health and wellbeing [1,2]. General cognitive ability (usually
denoted g) is a quantitative trait, and is assessed using cognitive
ability tests. Empirical evidence for g was first described by
Spearman [3] who found that diverse mental capabilities tended to
show positive covariation. The general intelligence factor, g,
accounts for about 50% of the total variance when a number of
diverse mental tests are administered to population samples [4].
The g factors derived from very different cognitive test batteries
rank people almost identically [5], and intelligence differences are
highly stable across the human lifecourse [6]. Two major facets of
intelligence are crystallized (gc) and fluid (gf) intelligence. Crystal-
lized-type intelligence is characterised by a relative lack of decline
with age [7], and is typically assessed using tests of acquired
knowledge, most often vocabulary. Types of cognitive ability that
are termed ‘fluid intelligence’ tend to decline with age from young
or middle adulthood [7], and are assessed using unfamiliar,
sometimes abstract materials, and involve on-the-spot thinking,
often under time pressure, and rely relatively little on prior
knowledge. Intelligence is substantially heritable [8,9] and,
although variants in a number of candidate genes have shown
significant associations, few have replicated [10,11]. This is true
for many complex traits: even in the most highly heritable, such as
height, known variants account for only a small proportion of the
observed heritability [12]. Several hypotheses have been proposed
as to where this ‘‘missing heritability’’ resides [13,14]. These
include common variants of small effect [15], rare variants with
large effects [16], epistatic interactions [17], epigenetic factors [18]
as well as other forms of genetic variation beyond single nucleotide
polymorphisms (SNPs). One example of this last factor is structural
genetic variation, which includes copy number variation.
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Copy number variants (CNVs) are defined as segments of DNA
longer than 1kb present in variable numbers of copies across
individuals within a population sample [19]. CNVs are defined
relative to a normal copy number of two; hence, segments that are
present in more than two copies within an individual are classed as
duplications, and fewer than two are classed as deletions. CNVs
are observed ubiquitously throughout the genomes of humans [20]
and other organisms [21]. Older SNP genotyping arrays missed
some of this variation, but recent high density arrays include
multiple non-polymorphic markers in regions of known structural
variation, allowing more reliable detection of CNVs.
The Database of Genomic Variants [22] reports over 60,000
CNVs at more than 15,000 loci from 42 reported studies, that
collectively cover more than a third of the human genome.
Whereas 1kb is typically taken as the minimum length for a CNV,
the largest can span several megabases, and can potentially disrupt
multiple genes and/or regulatory regions, each of which may have
an effect on gene expression and phenotype [23]. Initial studies of
CNV prevalence [20] suggested extensive numbers of smaller
CNVs across populations. There is still some debate regarding the
best method to detect CNVs from SNP data [24,25]. Different
methods show marked variation in the number and extent of
CNVs detected from the same samples, and the reliability of
calling shorter CNVs is especially questionable. However, calls for
longer CNVs are more consistent between methods [26], are more
likely to represent true variants, and thus have the potential for
more robust replication. Therefore, the current study examines the
effect of longer, rare CNVs on human intelligence differences.
Specific CNVs have been associated with susceptibility to
illnesses including HIV-1 infection [27], autoimmune disorders
[28–31], and cancer [32]; nervous system disorders [33] such as
Alzheimer’s Disease [34], Parkinson’s Disease [35,36], epilepsy
[37]; and psychiatric disorders, including schizophrenia [38,39],
mental retardation [40–42], autism [43–46] and major depressive
disorder [47]. However, as most detected CNVs are relatively rare
within discovery cohorts [48], association tests for individual
CNVs will be of limited power to detect significant variants. An
alternative approach is to test jointly for the effect of multiple rare
CNVs on disease status, by comparing the overall CNV load
between cases and controls. The overall CNV load can be
measured as the total number of rare CNVs carried, the total
length of these CNVs, or the total number of genes they disrupt.
The method of examining overall CNV load has been applied to a
number of psychiatric and neurological disorders [49–51]. Here,
we apply it to variation in human intelligence, treated as a
quantitative trait, measured in community-dwelling older people.
A report by Yeo et al. [52] identified a significant association
between the extent of rare genetic deletions and Full-Scale
Intelligence Quotient (FSIQ), derived from the Wechsler abbre-
viated scale of intelligence [53], in a very small clinical sample of
patients undergoing treatment for alcoholism. The authors
acknowledged that there have also been findings of CNV
differences between controls and disorders that involve cognitive
deficits. Williams et al. [54] examined the effect of rare CNVs on
risk of Attention-Deficit Hyperactivity Disorder (ADHD), finding
significant differences in numbers of CNVs $500 kb between
cases and controls for total CNV burden. Patients with psychiatric
disorders such as schizophrenia and ADHD often display cognitive
deficits [55], suggesting that the burden associated with rare CNVs
may also have an effect on intelligence itself. Here we present
analyses of the effect of large, rare CNVs on measured intelligence
in cohorts of relatively healthy individuals with a total sample size
of more than 3,000 older people.
Methods
Ethics Statement
Ethical approval for the Lothian Birth Cohort 1921 study was
obtained from the Lothian Research Ethics Committee. Ethical
approval for the Lothian Birth Cohort 1936 study was obtained
from Scotland’s Multicentre Research Ethics Committee and the
Lothian Research Ethics Committee. Ethical approval for the
Aberdeen Birth Cohort 1936 study was obtained from the
Grampian Research Ethics Committee. Ethical approval for
Manchester and Newcastle Longitudinal Studies of Cognitive
Ageing Cohorts study was obtained from the University of
Manchester. Written consent was received from all participants
for their information to be stored in the relevant university
database and used for research.
Cohort Descriptions
Lothian Birth Cohort 1921. The Lothian Birth Cohort 1921
(LBC1921) is a longitudinal study of cognitive ageing conducted at
the University of Edinburgh. Individuals in the LBC1921 were
born in 1921 and were recruited and tested in old age, as described
elsewhere [6,56]. In total, 550 individuals (234 male, 316 female)
were tested at mean age 79.1 years (SD=0.6). Participants were
tested individually, and completed a battery of cognitive tests
including: The Moray House Test No. 12 (MHT) [57], Raven’s
Standard Progressive Matrices [58], Verbal Fluency [59], and
Logical Memory [60]. Participants also completed the National
Adult Reading Test (NART) [61].
Lothian Birth Cohort 1936. The Lothian Birth Cohort 1936
(LBC1936) is a longitudinal study of cognitive ageing conducted at
the University of Edinburgh. Individuals in the LBC1936 were
born in 1936 and were recruited and tested in old age, as described
elsewhere [62]. In total, 1091 individuals (548 male, 543 female)
were tested at a mean age of 69.5 years (SD =0.8). Participants
were tested individually on a large battery of cognitive tests [62]
including the MHT, and the following six tests from the Wechsler
Adult Intelligence Scale-IIIUK (WAIS-IIIUK [60]): Digit Symbol
Coding, Block Design, Matrix Reasoning, Digit Span Backwards,
Symbol Search, and Letter-number Sequencing. Participants also
completed the NART [61].
Aberdeen Birth Cohort 1936. The Aberdeen Birth Cohort
1936 (ABC1936) is a longitudinal study of cognitive ageing.
Individuals in the ABC1936 were born in 1936 and were recruited
and tested in old age as described elsewhere [6,56]. In total, 498
individuals (243 men, 255 women) were tested at mean age
64.6 years (SD=0.9). Cognitive tests completed were the NART
[61], Raven’s Standard Progressive Matrices [58], Rey Auditory
Verbal Learning Test (AVLT) [59], Digit Symbol and Block
Design sub-tests of the Wechsler Adult Intelligence Scale-Revised
[63], and the Uses of Common Objects Test [59].
Manchester and Newcastle Longitudinal Studies of
Cognitive Ageing Cohorts
The University of Manchester Age and Cognitive Performance
Research Centre (ACPRC) programme began in 1983 and has
documented longitudinal trajectories in cognitive function in 6371
older adults in the North of England. The group comprises 1917
men and 4454 women with mean age 65.6 years (SD=14.3) at
initial recruitment. Details of the battery of cognitive function tests
used in alternating batteries can be found in Rabbitt et al. [64].
The Dyne Steel DNA Archive for Ageing and Cognition was
established following invitation to all participating volunteers 1999
and 2004. This resulted in 1829 volunteers attending Manchester
CNVs and Cognition
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or Newcastle Universities, or being visited at home for blood
sample collection.
Construction of Cognitive Phenotypes
We constructed cognitive phenotypes of fluid- and crystallized-
type intelligence for each of the cohorts. To represent crystallized
intelligence (gc), we used the NART in the Lothian Birth Cohorts
of 1921 and 1936, and the Aberdeen Birth Cohort of 1936, and
the Mill Hill Vocabulary A and B vocabulary tests in the
Manchester and Newcastle cohorts. All are vocabulary-based tests
and are good representatives of the underlying construct of
crystallized intelligence. The fact that not all cohorts received
precisely the same vocabulary test introduces a phenotypic
heterogeneity that is only likely to slightly reduce the size of any
observed association between CNV indices and intelligence.
A general intelligence factor for fluid-type intelligence was
derived in the Scottish cohorts using principal components
analyses (PCA), with higher values of the components reflecting
better ability. Strictly speaking, PCA does not produce ‘factors’,
but this is a common usage. For the two Lothian Birth Cohorts,
and the Aberdeen Birth Cohort of 1936, the scores on a number of
fluid-type intelligence tests were subjected to PCA. In all cases,
inspection of the scree slope and the Eigenvalues-greater-than-one
criterion indicated a single component that was then extracted.
Individuals’ scores on the first unrotated principal component
were used to represent fluid-type general intelligence (gf). In
LBC1921, the tests used to construct gf were the Moray House
Test, Raven’s Matrices, Logical Memory, and Verbal Fluency. In
LBC1936, the six tests from the WAIS-IIIUK described above
were used to construct gf. The tests used to define gf in ABC1936
were Raven’s Progressive Matrices, Digit Symbol, Uses of
Common Objects, and AVLT. The first principal component
accounted for 49% of variance in ABC1936, 56% in LBC1921
and 51% in LBC1936. The range of tests administered to the
LBC1936 sample allowed the construction of the same gf battery
used in LBC1921 using the LBC1936 data, and the correlation
between the gf scores derived from two different sets of tests on
LBC1936 was ,0.7. For the Manchester and Newcastle cohorts, a
general fluid-type intelligence ability factor, gf, was obtained from a
random effects model fitted by maximum likelihood to the
standardized age regressed residuals obtained for each sex from
tests including the Alice Heim 4 (AH4) parts 1 and 2 general
intelligence tests. Detailed task descriptions can be found in Rabbit
et al. [63]. The gf scores were derived separately for males and
females in the Manchester and Newcastle cohorts. Although
different tests were used to construct the general fluid intelligence
factors between cohorts, the correlation between such factors when
they are derived on the same sample tends to be very high [5,65].
All phenotypes described above were corrected for age, and for sex
for those not derived separately by gender. Standardized residuals
were used in all subsequent analyses.
SNP Genotyping and Quality Control
Genomic DNA was isolated using standard procedures at the
Wellcome Trust Clinical Research Facility (WTCRF) Genetics
Core, Western General Hospital, Edinburgh for LBC1936 and
ABC1936, and Medical Research Council Technology, Western
General Hospital, Edinburgh for LBC1921. The UK DNA
Banking Network was used for the Manchester and Newcastle
Dyne-Steele samples. In total, 3782 samples were genotyped at the
WTCRF Genetics Core (http://www.wtcrf.ed.ac.uk) using the
Illumina610-Quadv1 chip (LBC1936 N=1,042; LBC1921
N=526; ABC1936 N=456; Manchester N= 901; and Newcastle
N= 877).
Samples were subjected to the following quality control (QC)
procedures: individuals where self-reported gender disagreed with
genetic evidence were removed. Pairwise IBD between individuals
was estimated and, where it was greater than 0.25, one of each
pair was removed from the analysis. Samples with SNP call rate
,0.95, and those showing evidence of non-Caucasian origin by
multi-dimensional scaling were also removed. After QC, a total of
3,511 samples remained (LBC1936 N=1,005; LBC1921 N=517;
ABC1936 N=426; Manchester N= 805; and Newcastle N= 758).
SNPs were retained for analyses that met the following criteria:
call rate $0.98, minor allele frequency $0.01, and Hardy-
Weinberg Equilibrium test with P$0.001. A total of 549,754 SNPs
passed these QC criteria and, with the inclusion of a further
21,890 non-polymorphic markers in known CNV regions, 571,644
markers in total were used to call CNVs.
CNV Calling and Quality Control
CNV calling used Log-R-Ratio (LRR) and B-allele Frequency
(BAF) values normalised and extracted from raw signal data using
Illumina’s Genome Studio software. CNV calling was performed
using the detect_cnv.pl script from PennCNV [66], and the
QuantiSNP package [67]. Only variants that were called by both
algorithms were used in the analysis. Where CNV boundaries
were not identical between the two algorithms, the start and end of
the overlapping region were taken as the CNV boundaries.
Quality control steps [54] were applied at the level of sample
quality, and of individual CNVs. Twenty samples were genotyped
in duplicate to check consistency of genotype calling. Before QC
steps were implemented, 47% of total CNVs called were common
to both samples, increasing to 67% as restrictions on CNV length
($ 500kb) were put in place. After QC, the sample in each pair
with the lower SNP call rate was excluded from further analysis.
To investigate the effect of rare CNVs, the QC and selection
procedures of Williams et al. [54] were followed. Briefly, samples
with standard deviation of Log-R Ratio across all markers greater
than 0.3 were excluded, as were samples with 30 or more CNVs
called at longer than 100kb, due to the unreliability of these calls.
Quality control was also performed at the level of individual
CNVs, with variants that spanned fewer than 15 contiguous
markers discarded. Any adjacent CNVs that appeared to be
artificially separated by the calling algorithm were merged: CNVs
were candidates for merging when pairs of adjacent variants on
the same chromosome, of the same copy number state, were
greater than 200kb in length and separated by a distance of less
than half the total length of the merged variant. LRR and BAF
data for all candidate merges were inspected visually. To
investigate the effect of only rare variants, CNVs present in
greater than 1% of each cohort were discarded from analysis.
CNV boundaries do not necessarily correspond exactly between
samples, so variants were removed where any marker along their
length was called in a CNV region in greater than 1% of each
cohort. We investigated the effect of removing common CNVs
using the 1% criterion on the entire sample, rather than individual
cohorts, and found no differences in the significance of results
between the two sets of data (not shown).
Modelling CNV load
To investigate the effect of CNV load, we derived three
variables for each individual: the total number of CNVs that
passed the QC criteria outlined above; the total length of these
variants; and the number of genes disrupted by these CNVs.
Genes were counted as ‘disrupted’ if there was any overlap
between called CNV regions and known genetic co-ordinates +/
220 kb. The effect of CNV load on intelligence was investigated
CNVs and Cognition
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by fitting linear regression models to derived intelligence (g) factors
and test scores. A number of regression models were fitted, using
residualised gf and gc factor scores, corrected for age and sex effects,
against total number of CNVs (rate), total CNV length, and the
total number of genes disrupted, with ‘cohort’ fitted as a covariate.
CNV regions
Numerous copy-number variable regions have been implicated
in mental health disorders. Williams et al. [54] identify 20 regions
that have been associated with schizophrenia or autism spectrum
disorders. We investigated the effect of these specific variants in
our cohorts; i.e., we checked whether any individuals carried the
disease-associated variants reported in autism spectrum disorders
[45] or schizophrenia [51]. Where more than two individuals
within the sample carried one of these variants, the differences in
means of the carriers and non-carriers were tested using a t-test in
R. Permutation analysis was performed to generate corrected p-
values, on 100,000 permutations of the data. For each permuta-
tion, phenotypic values were permuted with reference to
individual IDs, and a t-test was performed for each CNV region
identified in Williams et al. [54]. The maximum test statistic of
these 20 tests was retained at each permutation. Observed p-values
were compared to the distribution of test statistics, with empirical
p-values calculated for each region as the proportion of
permutations where the maximum test statistic was greater than
the observed statistic.
Results
Following the QC procedures outlined above, 3133 individuals
remained with phenotypic information for gf, and 3210 for gc. The
CNVs used in subsequent analyses were those that fulfilled the QC
procedures outlined above, and were called as CNVs by both
QuantiSNP and PennCNV. For the samples providing the
cognitive phenotypes gf, and gc, the total numbers of long, rare
CNVs at $500 kb present in #1% of the cohort samples was 167
for both phenotypes. This gives overall CNV rates of 0.053 and
0.052 CNVs per individual for gf and gc (tables 1 and 2), with the
slight discrepancy in total CNV counts due to different numbers of
individuals with each phenotype. Most individuals carried no rare
CNVs and, of those carrying any, the majority carried a single
variant, with only nine individuals carrying more than one
(Tables 3 and 4). Variants are observed across all autosomes
throughout the sample, with more observed on longer chromo-
somes. The numbers of genes disrupted by these CNVs are shown
in Tables 5 and 6 for gf and gc respectively, determined by
comparing CNV boundaries to genetic start and end co-ordinates
(+/220 kb) and counting the number that overlap.
A linear regression model was fitted on total CNV rate (number
of CNVs called) per individual, fitting cohort as a covariate,
summarised in Tables 7 and 8 for gf and gc respectively,. Results
are also shown for similar regressions performed on the total
length of CNVs per individual, and for the number of genes
disrupted by CNVs. Models were fitted using data from all types of
CNV, and for deletions and duplications separately. None of the
fitted regression models were significant at p,0.05 for CNV
effects. For numbers of rare CNVs, we grouped individuals into
‘‘carriers’’ and ‘‘non-carriers’’ and compared the g scores in these
two groups. We found no significant differences between them, for
all CNVs, or for deletions or duplications alone (data not shown).
We also examined the effect of shorter, rare CNVs, at lengths
100–200 kb and 200–500 kb. These data are presented in
Tables S1 and S2.Of these tests, the majority showed no
association with either fluid or crystallized intelligence, but one
Table 1. Total CNV burden in each cohort for fluid-type
intelligence (gf).
All CNVs Deletions Duplications
Cohort
Sample
Size Load Rate Load Rate Load Rate
ABC1936 346 12 0.035 2 0.006 10 0.029
LBC1921 482 24 0.050 8 0.017 16 0.033
LBC1936 877 47 0.054 15 0.017 32 0.037
Manchester 730 44 0.060 12 0.017 32 0.044
Newcastle 698 40 0.057 4 0.006 36 0.052
Total N 3133 167 0.053 41 0.013 126 0.040
Total N represents the number of individuals with gf phenotypes, and high
quality genetic data used to call CNVs. Load is the total number of CNVs
counted in each cohort, called by both PennCNV and QuantiSNP, that passed
quality control criteria, namely longer that 500 kb, and present at a frequency
of 1% or less within each cohort, and Rate is the average number of such CNVs
per individual within each cohort, with totals for All CNVs called, and separated
into Deletions and Duplications.
doi:10.1371/journal.pone.0037385.t001
Table 2. Total CNV burden in each cohort for crystallized-
type intelligence (gc).
All CNVs Deletions Duplications
Cohort
Sample
size Load Rate Load Rate Rate Load
ABC1936 412 12 0.029 2 0.005 10 0.024
LBC1921 492 24 0.049 8 0.016 16 0.033
LBC1936 887 47 0.053 15 0.017 32 0.036
Manchester 723 44 0.061 12 0.017 32 0.044
Newcastle 696 40 0.058 4 0.006 36 0.052
Total N 3210 167 0.052 41 0.013 126 0.039
Total N represents the number of individuals with gc phenotypes, and high
quality genetic data used to call CNVs. Load is the total number of CNVs
counted in each cohort, called by both PennCNV and QuantiSNP, that passed
quality control criteria, namely longer that 500 kb, and present at a frequency
of 1% or less within each cohort, and Rate is the average number of such CNVs
per individual within each cohort, with totals for All CNVs called, and separated
into Deletions and Duplications.
doi:10.1371/journal.pone.0037385.t002
Table 3. Distribution of long, rare CNVs in each cohort for
individuals with a fluid-type intelligence (gf).
# Rare
CNVs ABC1936 LBC1921 LBC1936 Manchester Newcastle Total
0 334 458 830 686 658 2966
1 12 22 41 36 37 153
2 0 1 3 4 0 8
3 0 0 0 0 1 1
Total 346 482 877 730 698 3133
Total numbers of individuals with gf phenotype carrying 0–3 long ($500 kb),
rare (, 1% frequency) copy number variants in each cohort.
doi:10.1371/journal.pone.0037385.t003
CNVs and Cognition
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test, total CNV counts for deletions in the range 200–500 kb,
showed a nominally significant p-value of 0.039 with gf, although
this is not robust to multiple testing correction. Yeo et al. [52]
reported a significant association between rare deletions and Full-
Scale IQ, but their definition of ‘rare’ (5%) differs from our 1%
threshold, and other QC criteria differ. Repeating the analysis
using the QC criteria of Yeo et al. on our samples failed to
replicate their association (Tables S3 & S4).
Previous studies that have investigated the effect of rare CNVs
on so-called neurocognitive disorders found several copy number
variants that have an effect on these traits [39,43,51,68–74].
Because these disorders also involve cognitive deficits, we
examined variants declared significant in studies for autism and
schizophrenia in our samples. The results are listed in Table S5.
Where more than two individuals carried any particular variant,
the sample was split into carriers and non-carriers, and differences
in intelligence between these two groups were assessed using t-
tests. Of the twenty loci examined, one region, 16p13.11, had four
CNV carriers within our sample, and a region overlapping
SHANK3 had three. The 16p13.11 region showed no evidence of
an effect on either gf or gc, but SHANK3 showed a nominally
significant effect at p = 0.006 for fluid-type intelligence. Permuta-
tion analyses were performed to generate corrected p-values:
2100,000 permutations were performed, the largest test statistic
taken over all 20 CNV regions, and the observed test statistic for
each region compared to this distribution to calculate an empirical
p-value. Following this procedure, SHANK3 remained significant
for gf with a corrected p-value of 0.01.(Table S5).
Discussion
Intelligence differences are substantially heritable, but studies to
date have failed to find replicable associations between SNPs and
cognitive traits that account for variation in intelligence in the
normal population [8,11]. One potential source of the missing
heritability is copy-number variation. Following a similar ap-
proach to Williams et al. [54], in which the combined effect of rare
CNVs on variation in ADHD was investigated in a sample of 366
cases and 1047 controls, we examined whether variation in rare
CNVs had any effect within older cohorts with intelligence
distributions in the normal range had any effect on the variation in
cognitive ability. No significant combined effect of rare CNVs was
found on intelligence in our combined sample of over 3,000
elderly individuals.
We found that the total load of CNVs longer than 500 kb per
individual was not significantly associated with fluid- or crystal-
lized-type intelligence phenotypes. Neither was total length of copy
number variants, nor the total number of genes disrupted by rare
CNVs. Testing for differences in intelligence between individuals
carrying CNVs known to effect neurocognitive phenotypes, and
non-carriers found a suggestive effect of SHANK3 on fluid
intelligence scores. SHANK3 is a post-synaptic density protein
involved in the regulation of synaptic transmission, and has been
implicated in both autism and schizophrenia. SHANK3 is within
the region of the chromosome 22q13.3 deletion syndrome, which
is characterized by neonatal hypotonia, global developmental
delay, severe cognitive deficits, normal to accelerated growth,
absent to severely delayed speech, autistic behaviour, and minor
dysmorphic features [73,75]. Haploinsufficiency of this gene as a
major causative factor in the neurologic symptoms of 22q13
deletion syndrome [76], and Gauthier et al. [77] identified two de
novo mutations (R1117X and R536W) in two families with
schizophrenia, in patients also displaying borderline or mild
mental retardation. A recent GWAS study on cognitive pheno-
types which used SNPs to tag common CNVs [78], found no
significant association between these tagging markers and any of
the measured cognitive phenotypes after correcting for multiple
testing. This study by Need et al. [78] focussed on associations
between cognitive phenotypes and specific copy-number variants
associated with psychiatric illnesses in a sample of 1,000. Similarly,
Saus et al. [79], using a candidate gene approach, found no
significant differences between rare variants in cases and controls
Table 4. Distribution of long, rare CNVs in each cohort for
individuals with a crytallized-type intelligence (gc).
# Rare
CNVs ABC1936 LBC1921 LBC1936 Manchester Newcastle Total
0 400 468 840 679 656 3043
1 12 22 41 36 37 148
2 0 1 3 4 0 8
3 0 0 0 0 1 1
Total 412 492 887 723 696 3210
Total numbers of individuals with gc phenotype carrying 0–3 long ($500 kb),
rare (,1% frequency) copy number variants in each cohort.
doi:10.1371/journal.pone.0037385.t004
Table 5. Total genes disrupted by CNVs in each cohort for
fluid-type intelligence (gf).
All CNVs Deletions Duplications
Cohort
Sample
Size
Gene
Load Rate
Gene
Load Rate
Gene
Load Rate
ABC1936 346 37 0.107 8 0.023 29 0.084
LBC1921 482 60 0.125 10 0.021 50 0.104
LBC1936 877 144 0.164 56 0.064 88 0.100
Manchester 730 81 0.111 19 0.026 62 0.085
Newcastle 698 120 0.172 4 0.006 116 0.166
Total 3133 442 0.141 97 0.031 345 0.110
Gene load is calculated as the number of genes whose co-ordinates +/220 kb
intersect with a CNV that passes QC checks (length $500 kb, and frequency
#1%). Rate is the average number of such CNVs per individual.
doi:10.1371/journal.pone.0037385.t005
Table 6. Total genes disrupted by CNVs in each cohort for
crystallized-type intelligence (gc).
All CNVs Deletions Duplications
Cohort
Sample
Size
Gene
Load Rate
Gene
Load Rate
Gene
Load Rate
ABC1936 412 37 0.090 8 0.019 29 0.070
LBC1921 492 60 0.122 10 0.020 50 0.102
LBC1936 887 144 0.162 56 0.063 88 0.099
Manchester 723 81 0.112 19 0.026 62 0.086
Newcastle 698 120 0.172 4 0.006 116 0.167
Total 3210 442 0.138 97 0.030 345 0.108
Gene load, is calculated as the number of genes whose co-ordinates +/220 kb
intersect with a CNV that passes QC checks (length $500 kb, and frequency
#1%). Rate is the average number of such CNVs per individual.
doi:10.1371/journal.pone.0037385.t006
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in major depressive disorder, bipolar disorder, schizophrenia or
anxiety disorders, testing a control group of 341 individuals against
case samples of ,200 per disorder.
Comparing our results to Yeo et al. [52], who found significant
associations between rare deletions and variation in intelligence in
a sample of 77 individuals, we failed to replicate their observed
significant association between the extent of rare deletions and
general intelligence, even when applying the same set of CNV QC
criteria to our larger data set There are several possible reasons
why this may be so. Whereas the phenotypic measures of
intelligence that were used are broadly comparable, there are
slight differences in our CNV calling and QC methods, the major
one being our use of a minimum 500 kb cut-off in CNV length,
but no such cut-off was used by Yeo et al. This is apparent from the
overall rate of CNVs per individual in the two studies, with Yeo
et al. finding an average of 17.42 CNVs per individual, with an
average deletion rate of 10.95 (SD=5.48) and insertion rate of
6.47 (SD=9.82); compared to our observations of ,0.05 in total,
a substantial disparity between the two rates, and between Yeo
et al. and other studies of ‘rare’ CNVs which include a length cut-
off [80]. The rationale behind such a cut-off is that the calls for
longer CNVs are more accurate than shorter variants, and
including short variants in an association analysis may increase the
probability of type-I errors. When applying the QC criteria of Yeo
et al. to our data (removing the length restriction, and excluding
common CNVs at the 5% threshold), the observed average rate of
CNVs called per individual was 15.48 (SD=7.59). None of the
regression analyses performed on CNVs called using these criteria
showed a significant effect in our sample (Tables S3 and S4).
The samples studied in the present report comprise individuals
within the normal cognitive range and we would expect the rate of
CNVs detected to be similar to that obtained in other groups of
healthy individuals that have undergone the same CNV quality
control and selection procedures. Several studies have investigated
the effect of long, rare CNVs on disease susceptibility, using the
same length and frequency criteria employed here. Comparing
our rates of CNV detection to the control groups of these studies,
our observed values of 0.052 and 0.053 are comparable to the
values of 0.05 observed by Blauw et al. [49], slightly lower than the
value of 0.075 reported by Williams et al. [54], and lower than the
values of 0.12 reported by the ISC [51], 0.17 in Pinto et al. [50],
and 0.1924 in Bochukova et al. [81]. Some of these discrepancies
can partially be accounted for by differences in genotype platforms
and CNV calling algorithms. Blauw et al.[49] genotyped their
control samples using a number of different platforms, but
analysed only CNVs called by markers common to all: these
were effectively the markers present on the HumanHap 300 array,
comprising ,300 K SNP markers and lacking CNV specific
probes. The ISC study [51] used genotypes derived from
Affymetrix 5.0 and 6.0 arrays, and noted differences between
these two arrays within their study. Bochukova et al. [81] also used
the Affymetrix 6.0, whereas Pinto et al. [50] used the Illumina 1M
chip for genotyping, and both observed a higher rate of CNVs per
sample. Whenever a minimum number of SNPs is used as a
criterion to define a CNV, there will be de facto more CNVs called
on chips with higher marker densities.
Although the absolute rates of CNVs called differ between
studies, the proportions of deletions detected compared to
duplications are more consistent between studies. Of our total
observed variants, 24.6% (41/167),are deletions in, compared to
28.0% in Bochukova et al. [81], 28.3% in ISC, and 29.2 % in
Pinto et al [50]. The anomalously large proportion of 72.0%
deletions in Blauw et al. [82] may be due to the set of markers used
detecting more deletions. The 16.7% duplications called in
Williams et al. [54] is smaller than other studies, perhaps due to
the small sample size.
There are several other reasons why we may have failed to
detect any effect of rare CNVs on cognitive ability in the cohorts
Table 7. Tests of significance of CNV load on regression on fluid-type (gf) intelligence.
All Dels Dups
Effect p-val Emp p-val Effect p-val Emp p-val Effect p-val Emp p-val
CNV count 20.002 0.927 0.913 20.010 0.592 0.606 +0.004 0.826 0.822
CNV length 20.014 0.419 0.425 20.018 0.326 0.334 -0.007 0.712 0.719
Genes disrupted 20.020 0.261 0.283 20.035 0.053 0.055 -0.004 0.802 0.822
Effect sizes are reported as standardized b values for each regression model, fitting total CNV count, length and number of genes disrupted against fluid-type (gf)
intelligence for rare CNVs of length $500 kb present at #1% frequency in each cohort. Regression models fitted for all CNVS (all), deletions only (Dels) and duplications
only (Dups). P-values for regression tests are given for each regression, along with empirical p-values, calculated from 100,000 permutations of each model.
doi:10.1371/journal.pone.0037385.t007
Table 8. Tests of significance of CNV load on regression on crystallized-type (gc) intelligence.
All Dels Dups
Effect p-val Emp p-val Effect p-val Emp p-val Effect p-val Emp p-val
CNV count 20.012 0.513 0.502 20.006 0.743 0.743 -0.010 0.567 0.592
CNV length 20.005 0.774 0.752 20.007 0.703 0.687 -0.002 0.910 0.907
Genes disrupted 20.010 0.555 0.553 20.025 0.150 0.149 +0.002 0.926 0.938
Effect sizes are reported as standardized b values for each regression model, fitting total CNV count, length and number of genes disrupted against crystallized-type (gc)
intelligence for rare CNVs of length $500 kb present at #1% frequency in each cohort. Regression models fitted for all CNVS (all), deletions only (Dels) and duplications
only (Dups). P-values for regression tests are given for each regression, along with empirical p-values, calculated from 100,000 permutations of each model.
doi:10.1371/journal.pone.0037385.t008
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analysed here. Primary amongst them, we are unlikely to have
captured all of the genetic variation present within our samples.
The Illumina 610 Quad chip used for genotyping in this study
contains several non-polymorphic markers in known copy number
variable regions, but will still not capture all of the variation
present. With subsequent developments in microarrays, such as
the Illumina 1M array used by Yeo et al., and the advent of
reasonably priced whole-genome sequencing, we could capture a
higher proportion of the actual variation. Other factors beyond
genetic and structural variation may also contribute towards
variation in general cognitive ability, including environmental
variation and gene methylation or other epigenetic effects.
Significant regions for rare CNVs reported in other neurocognitive
disorders are not found significant by genome-wide associations
using SNPs. Need et al. [78] suggest that looking for the effect of
rare variants enriched in schizophrenia patients within a healthy
population may reveal an association. Of the regions we
examined, SHANK3 remained significant following permutation
analysis, suggesting that this gene may be involved in normal
variation in fluid intelligence. However, of the three CNV carriers
identified in our samples that overlap the SHANK3 region, two
carried duplications (copy number 3) and one a deletion (copy
number 1), suggesting that imbalance rather than copy number per
se may be important, but this counter-intuitive observation
requires further investigation.
Many illnesses are associated with lower cognitive ability, and
there is evidence that these states often involve structural genetic
variation. Cognitive impairment is often a symptom in genomic
syndromes associated with specific large-scale structural variation,
including Williams-Beuren, Smith-Magenis, and Velo-Cardio-
Facial Syndrome amongst others [83]. These syndromes are
characterised by recurrent deletions or duplications at specific loci,
which are large enough to be detected using Fluorescence In-Situ
Hybridisation (FISH) or other microscopic techniques. Recent
advances in microarray technology have allowed detection and
characterisation of sub-microscopic structural variants, and found
them to be ubiquitous throughout the genome. These copy-
number variants are a major source of normal human genetic
variation [84], but have also been found to be associated with
complex disorders, including many neuro-psychiatric conditions,
(for example, ADHD, depression, schizophrenia and autism-
spectrum disorders).
To conclude, we find that, within the analytical limitations of
the detection system available to us, there is no evidence for the
effect of total CNV load on intelligence within the normal older
population. Looking at specific CNV regions, we find evidence to
suggest that copy number variation in the SHANK3,region where
copy number variation has been previously associated with
susceptibility to autism and schizophrenia, is associated with
normal variation in fluid intelligence. However, our study does not
preclude further contributions of CNVs at either extremes of the
normal range of intelligence, or indeed on an individual by
individual basis. New tools, including whole genome resequencing
of individuals and their relatives with life-course measures of
intelligence would be valuable in further resolving the important
issue of identifying genetic contributions to individual differences
in intelligence.
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